Adenocarcinoma of the endometrium is one of the most
common cancer in women. Therefore, the development of
new prognostic evaluation methods and more effective
therapies requires a better understanding of the molecular
mechanisms that control invasion and metastases. Few data
are available on the expression of galectins in endometrial
cancer.